Study justifies L-DOPA therapy for Angelman syndrome

November 12, 2012
This is an in vivo voltammograms showing higher dopamine (DA) release in the nucleus accumbens (NAc) and lower release in the dorsal striatum of Angelman syndrome model mice (Ube3a m-/p+) compared to wild-type mice (WT). Credit: Image courtesy of C.J. Malanga, MD, PhD

Last year a clinical trial of L-DOPA—a mainstay of Parkinson's disease therapy—was launched for Angelman syndrome, a rare intellectual disorder that shares similar motor symptoms such as tremors and difficulty with balance. The clinical trial is based on a 10-year-old case report showing benefit with the drug, but few studies since have explored the neurological justification for using L-DOPA to treat parkinsonian features in Angelman syndrome.

New research from the University of North Carolina School of Medicine, conducted in animal models of the disorder, now provides justification for this . The study, published online ahead of print on Nov. 12 by the , suggests that L-DOPA could compensate for a loss of the neurochemical in the brain's motor pathways and improve . However, it also indicates that the drug could add to an already increased amount of dopamine in the brain's reward pathways and thus have unanticipated consequences on emotion and attention.

"The results were extremely surprising, because we don't know of any other disorder where dopamine is affected one way in one and the opposite way in another," said Benjamin D. Philpot, PhD, associate professor of and physiology at UNC.

"If what we see in humans mirrors what we see in mice, then it does provide some optimism that L-DOPA might provide benefit for tremor," said C.J. Malanga, MD, PhD, associate professor of neurology at UNC. "But it also raises caution that researchers might want to consider assessing other aspects of Angelman syndrome that might be affected by dopamine—not just motor symptoms but also other neuropsychiatric features." Malanga and Philpot are senior authors of the study.

Angelman syndrome affects about every one out of every 15,000 people. Individuals with the disorder have minimal – some never speak a single word – as well as seizures and motor problems. It is caused by defects in UBE3A, a gene involved in the development of the brain's wiring. Much of what has been learned about this gene has come from a mouse model lacking UBE3A.

Philpot and Malanga decided to use these Angelman syndrome model mice to explore how dopamine is affected in Angelman syndrome. Dopamine is a well-known neurotransmitter, one of many chemicals responsible for transmitting signals between neurons in the brain. In their experiments, the researchers found that the behavioral deficits seen in the Angelman syndrome model were not due to the loss of dopamine-producing brain cells—as in Parkinson's disease—or reduced production of the important neurochemical.

Rather, they found that it was associated with differences in release of the dopamine molecule from brain cells. Specifically, dopamine release was decreased in one brain pathway—the motor or nigrostriatal pathway—and increased in another—the reward or mesolimbic pathway. But instead of having a greater effect on reward, dopamine also appeared to be less effective at motivating behavior in these mice.

"One of the interesting features of people with Angelman syndrome is that they generally have a very happy disposition and a lower threshold for humor. It is interesting that we found this effect in the reward pathway, because it could provide a biological basis for this happy disposition," said Philpot.

Malanga cautions that this happy disposition, as well as the lack of communication skills, might make it hard for researchers to tell if their patients are experiencing negative consequences of an altered reward pathway, such as changes in mood or compulsive behaviors. Therefore, he recommends that assess many different outcome measures to ensure that L-DOPA treatment does not lead to unanticipated outcomes.

Explore further: Brain cell activity imbalance may account for seizure susceptibility in Angelman syndrome

Related Stories

Brain cell activity imbalance may account for seizure susceptibility in Angelman syndrome

June 6, 2012
New research by scientists at the University of North Carolina School of Medicine may have pinpointed an underlying cause of the seizures that affect 90 percent of people with Angelman syndrome (AS), a neurodevelopmental ...

People with Parkinson's more likely to have leg restlessness than restless leg syndrome

November 9, 2011
People with Parkinson's disease may be more likely to have a movement disorder called leg motor restlessness, but not true restless legs syndrome as previous studies have suggested, according to a study published in the Nov. ...

New discovery could lead to treatment for Angelman syndrome

December 21, 2011
Results of a new study from the University of North Carolina at Chapel Hill may help pave the way to a treatment for a neurogenetic disorder often misdiagnosed as cerebral palsy or autism.

Recommended for you

Molecular hitchhiker on human protein signals tumors to self-destruct

July 24, 2017
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found.

New vaccine production could improve flu shot accuracy

July 24, 2017
A new way of producing the seasonal flu vaccine could speed up the process and provide better protection against infection.

Researchers develop new method to generate human antibodies

July 24, 2017
An international team of scientists has developed a method to rapidly produce specific human antibodies in the laboratory. The technique, which will be described in a paper to be published July 24 in The Journal of Experimental ...

A sodium surprise: Engineers find unexpected result during cardiac research

July 20, 2017
Irregular heartbeat—or arrhythmia—can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising ...

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

'Smart' robot technology could give stroke rehab a boost

July 19, 2017
Scientists say they have developed a "smart" robotic harness that might make it easier for people to learn to walk again after a stroke or spinal cord injury.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Tom_Hennessy
1 / 5 (2) Nov 13, 2012
Increased iron in the brain is known to cause tremors and tremors have been decreased by iron removal.
"After 6 months of therapy the patient's gait had improved and a reduction in the incidence of choreic dyskinesias was observed"

Drugs used in Angelman's Syndrome have iron chelating properties.

"Topoisomerase inhibitors can turn on the father's inactive copy of the gene in brain cells of mice with a version of Angelman syndrome."

"Dual ability to chelate iron and inhibit top2alpha activity."

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.